Circulating hormones were measured via ELISA (MesoScale Discovery, total GLP-1 and PYY assays, UK) at the Core Biochemical Assay Laboratories, Cambridge, UK
Does the 28-day rule apply if most of the vial is still full
Semaglutide for Treatment of NAFLD and NASH Following our exploration of liraglutide, semaglutide enters the stage as a promising candidate for NAFLD/NASH, particularly for patients across the diabetes spectrum
Monitoring Side Effects: Regular follow-ups allow for the monitoring of any side effects and adjustments to the treatment plan
It is increasingly discussed in longevity and preventive-medicine circles as a way to achieve: Metabolic balance without extreme appetite suppression Sustained tolerability by avoiding gastrointestinal side effects Lower cost and simplified maintenance regimens Long-term receptor engagement for cardiometabolic and neuroprotective benefits While this approach remains off-label and under formal investigation, the biological rationale is strong: GLP-1 signaling is not binary but dose-responsive, and even partial activation may influence inflammatory, vascular, and cognitive pathways linked to aging